The Latest News in the Peptide World

Q2 2024 Edition

Welcome to our Q2 2024 Peptide News Roundup! This quarter has been groundbreaking for the peptide space, with major strides in corporate partnerships, cutting-edge research, and technological innovations. We're changing our format slightly, and doing a quarterly review and dividing it into two exciting sections: the first set of articles showcases notable industry news and clinical advancements, including major moves by Novartis and Eli Lilly. The second set delves into scientific breakthroughs and innovative technologies that are pushing the boundaries of peptide research. Dive in to discover how these developments are shaping the future of medicine and biotechnology!

Industry News and Clinical Advancements

01. Novartis Pays PeptiDream $180M as Radiopharma Big Bang Continues

Novartis expands its peptide-drug conjugate (PDC) collaboration with PeptiDream by investing $180 million. This partnership focuses on developing targeted radiotherapy treatments for cancer using PDC technology.


02. Lilly Signs $140M Upfront Partnership with Radiopharmaceutical Company

Eli Lilly enters a $140 million upfront deal with Radiopharmaceuticals to develop innovative cancer therapies, aligning with its strategy to expand its radiopharmaceutical portfolio.


03. Health Tech Startup Dandelion Health Launches Data Library

Dandelion Health launches a comprehensive data library aimed at accelerating insights into GLP-1 drugs, supporting advancements in personalized medicine through extensive datasets.


04. KU Cancer Center Researcher Secures $1.4M Grant for Peptide Therapy

A KU Cancer Center researcher secures a $1.4 million grant to develop a peptide therapy for prostate cancer, supporting preclinical studies for this innovative treatment.


05. Eli Lilly's Tirzepatide Scores Again in Sleep Apnea Trials

Eli Lilly's tirzepatide shows positive results in sleep apnea trials, demonstrating its potential to treat multiple conditions, including diabetes and obesity.


06. Entera Bio to Present Phase 1 Data and Achieves Regulatory Milestone for PTH 1-34 Peptide Tablets

Entera Bio will present phase 1 data for its PTH1-34 peptide tablets for hypoparathyroidism at the ENDO 2024 conference, aiming to offer a convenient treatment option. Additionally, Entera Bio achieves a regulatory milestone for its oral PTH 1-34 peptide, EB613, with the FDA expected to rule on qualifying bone mineral density as a surrogate endpoint within 10 months.

and here...

07. Darling Ingredients Identifies Collagen Peptide Profiles for Targeted Health Benefits

Darling Ingredients has identified specific collagen peptide profiles that offer targeted health benefits. These findings could lead to the development of new supplements and treatments aimed at improving joint health, skin elasticity, and overall well-being (Source: PR Newswire).


08. Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy

Treos Bio will present phase 2 trial results of PolyPEPI1018 combined with Roche’s PD-L1 inhibitor for treating metastatic colorectal cancer at the 2024 ASCO Annual Meeting.


09. Metsera Secures $290M in Funding, Focuses on Customizable Combos for Obesity

Metsera raises $290 million to develop customizable combination therapies for obesity, aiming to tailor treatments to individual patient needs.


10. Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration

Secarna Pharmaceuticals and Orbit Discovery are collaborating to develop peptide-conjugated targeted antisense oligonucleotide therapeutics, combining their strengths in peptide and oligonucleotide technologies.


11. NeuroBo Pharmaceuticals Doses First Patient in Phase 1 Obesity Trial

NeuroBo Pharmaceuticals begins dosing in its phase 1 trial evaluating DA-1726 for obesity, assessing the safety and efficacy of this novel peptide drug.


12. Viking Touts Promising Phase 1 Data for Weight Loss Pill

Viking Therapeutics announces promising phase 1 trial results for its weight loss pill, showing significant weight reduction in participants.


13. Donaldson and PolyPeptide Partner to Improve Sustainability in Peptide Manufacturing with Solvent Recovery Technology

Donaldson and PolyPeptide have partnered to enhance sustainability in peptide manufacturing through solvent recovery technology. This collaboration aims to reduce environmental impact and improve efficiency in the production process, aligning with industry trends towards greener practices.


Scientific Breakthroughs

01. UW's Baker Lab Researchers Make AI Strides in Drug Peptides

UW's Baker Lab researchers use AI to advance the development of drug peptides, potentially revolutionizing the drug discovery process.


02. Aligned Peptide Noodles Could Enable Lab-Grown Biological Tissues

Researchers have developed aligned peptide structures, referred to as "peptide noodles," which could be instrumental in creating lab-grown biological tissues. These structures provide the necessary scaffolding for tissue engineering, advancing the field of regenerative medicine (Source: Rice University).


03. Engineered Peptides Show Promise in Cancer Immunotherapy

Engineered peptides are proving to be effective in enhancing the immune system's ability to target and destroy cancer cells, offering new potential in cancer immunotherapy.


04. Bone-Enhancing Peptide Shows Promise as Therapeutic

Research on a bone-enhancing peptide shows promise for treating osteoporosis and musculoskeletal disorders by stimulating bone growth.


05. Revolutionizing Cysteine-Rich Peptide Production for Drug Discovery

A new method for producing cysteine-rich peptides could significantly advance drug discovery by overcoming previous synthesis challenges.


06. SecM Arrest Peptide Traps Pre-Peptide Bond Formation State of the Ribosome

The SecM arrest peptide halts the ribosome before peptide bond formation, providing new insights into protein synthesis regulation and potential antibiotic targets.


07. A Phage-Displayed Disulfide Constrained Peptide Discovery Platform Yields Novel Human Plasma Protein Binders

This study presents a platform for discovering novel peptide binders for human plasma proteins using phage display technology. The platform utilizes disulfide-constrained peptides, enhancing stability and binding affinity. The findings have potential implications for therapeutic development and diagnostics.


08. Neuropeptide in Blood Helps Diagnose Chronic Itch

A specific neuropeptide in blood can help diagnose chronic itch conditions, potentially leading to earlier and more accurate diagnoses.


09. Newly Discovered Peptide Could Treat Incurable Bacterial Infections

A new peptide has been identified that can treat antibiotic-resistant bacterial infections, offering hope for new treatments against persistent infections.


10. Treating Obesity Using GLP-1 Directed NMDA Receptor Inhibition

GLP-1 directed NMDA receptor inhibitors are being researched as a potential obesity treatment, combining the benefits of GLP-1 therapies with fewer side effects.


11. MORITS: An Improved Method to Predict Peptides from Heterologous Proteins that are Recognized by the Same T-Cell Receptor

The article introduces MORITS, a novel method for predicting peptides from heterologous proteins that can be recognized by the same T-cell receptor. This method could improve immunotherapy strategies by identifying cross-reactive peptides, enhancing the precision of immune responses in treatments.


12. Chemokine-Derived Oncolytic Peptide Induces Immunogenic Cancer Cell Death and Significantly Suppresses Tumor Growth

Researchers developed an oncolytic peptide derived from chemokines that induces immunogenic cancer cell death. This peptide significantly suppresses tumor growth, highlighting its potential as a novel therapeutic strategy in cancer treatment. The study emphasizes the importance of immunogenic cell death in oncology.


13. Drug Delivery Multifunctional Based Switchable Systems

Scientists are developing multifunctional, switchable drug delivery systems that can adapt to different therapeutic needs. These systems aim to enhance the precision and efficacy of drug delivery, reducing side effects and improving patient outcomes (Source:


14. Extracellular Vesicles Selective Capture by Peptide-Functionalized Hollow Fiber Membranes

The Institute on Membrane Technology develops a peptide-functionalized hollow fiber (HF) membrane module for the selective capture and enrichment of extracellular vesicles (EVs) from human cardiac progenitor cells. By modifying HF membranes with a copoly azide polymer and integrating them into a tangential flow filtration (TFF) process, the researchers achieved high purity EV isolation, removing contaminants such as albumin and preserving EV structural integrity. This scalable method offers a promising approach for EV-based diagnostic and therapeutic applications.


15. Thermodynamic and Molecular Dynamic Insights into How Fusion Influences Peptide-Tag Recognition of an Antibody

This research provides insights into how peptide fusion impacts the recognition by an antibody. Thermodynamic and molecular dynamics analyses reveal changes in binding affinity and specificity. These findings are crucial for designing more effective peptide-based therapeutics and diagnostic tools.


16. Imaging Technique Shows New Details of Peptide Structures

Advances in imaging technology have allowed scientists to visualize peptide structures with unprecedented detail. This breakthrough enhances the understanding of peptide interactions and can facilitate the development of new drugs and therapies (Source: X-MOL).


17. Innovative Peptide-Based Hydrogel Therapy for Virus Prevention

Researchers created a peptide-based hydrogel that can be used to prevent viral infections. This innovative approach offers a potential new method for controlling the spread of viruses and protecting public health (Source:


18. Vesicle Protrusion Induced by Antimicrobial Peptides Suggests Common Carpet Mechanism for Short Antimicrobial Peptides

The study examines the mechanism by which short antimicrobial peptides induce vesicle protrusion, suggesting a common carpet mechanism. This research advances the understanding of antimicrobial peptide action, which is vital for developing new antibiotics.


19. Peptide Vaccines Get an OS Update

This article discusses advancements in peptide vaccine design, focusing on thioamide substitution in the peptide backbone. This modification enhances resistance to proteolysis and improves binding to the MHC I complex, potentially increasing the efficacy of peptide vaccines.



Get the top 10 highlights monthly in your inbox

About Us

CSBio is a leading peptide and instrumentation manufacturing company located in Silicon Valley, California.

CSBio provides nonGMP and cGMP peptides, peptide APIs, research scale peptide synthesizers, commerical scale peptide synthesizers, DNA/RNA oligonucleotide synthesizers, and preparative HPLC purification equipment.

Peptide Contact

20 Kelly Court
Menlo Park, CA 94025


Instrumentation Contact

915 Linda Vista Ave
Mountain View, CA, 94043